Hannah Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hannah Nakamura has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ai Yoshihara
Department of Internal Medicine, Ito Hospital, Tokyo, Japan
1 shared publication - Akiko Sankoda
Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan
1 shared publication - Akira Iwase
Department of Obstetrics and Gynecology Gunma University Hospital Maebashi Japan
1 shared publication - Aya Yoshihara
Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan
1 shared publication - Erika Ota
Global Health Nursing; St.Luke’s International University; Tokyo Japan
1 shared publication - Hitomi Suzuki
Division of Women’s Internal Medicine, Integrated Center for Women’s Health, National Center for Child Health and Development, Tokyo 157-8535, Japan
1 shared publication
Latest Publications
- 1 April 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (4) , 519-530
Effects of Levothyroxine Treatment on Fertility and Pregnancy Outcomes in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Subclinical hypothyroidism, elevated thyroid-stimulating hormone (TSH) and normal free thyroxine (FT4) levels, is associated with multiple adverse pregnancy outcomes. Despite the uncertainty regarding the effectiveness of levothyroxine treatment on pregnancy outcomes in subclinical hypothyroidism, levothyroxine is widely administered with a threshold TSH level of 2.5 mU/L. The aim of this study is to investigate the efficacy of periconceptional levothyroxine treatment for subclinical hypothyroidism, including TSH levels >2.5 mU/L, and identify the characteristics of subclinical hypothyroidism that can benefit from levothyroxine treatment. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials from inception to February 2023. We analyzed the pooled effects of levothyroxine on subclinical hypothyroidism before and during pregnancy. The main outcomes before pregnancy were live birth, pregnancy, and miscarriage. The main outcomes during pregnancy were live birth, miscarriage, and preterm birth. We conducted subgroup analyses to compare the effects of levothyroxine on subclinical hypothyroidism with TSH levels of 2.5–4.0 mU/L and >4.0 mU/L. Results: Of the 795 studies identified, 25 full-text articles were screened for eligibility. Finally, five studies on pre-conception treatment with 763 participants and seven studies on treatment during early pregnancy with 2,504 participants were analyzed. Pre-conception levothyroxine treatment showed no effect in improving live births and pregnancies, or decreasing miscarriages (risk ratio (RR):1.41; 95% confidence interval (CI):0.84–2.36, RR:1.73; 95%CI:0.88–3.39, and RR:0.46; 95%CI:0.11–2.00, respectively). Levothyroxine treatment during pregnancy showed no effect in improving live births (RR:1.03; 95%CI:0.98–1.09) or decreasing miscarriage rates (RR:0.99; 95%CI:0.65–1.51). The effect of levothyroxine treatment on preterm birth during pregnancy was significantly different depending on the TSH values (p=0.04); a positive effect was shown in the subclinical hypothyroidism subgroup with TSH >4.0 mU/L (RR:0.47; 95%CI:0.20–1.10), while no effect was shown in the subgroup with TSH 2.5-4.0 mU/L (RR:1.35; 95%CI:0.79–2.31). Conclusions: Pre-conceptional levothyroxine treatment does not improve fertility or decrease the incidence of miscarriages. However, further well-designed studies are needed for pre-conceptional treatment, especially in TSH >4.0 mU/L. Levothyroxine treatment during pregnancy had a positive effect on preterm birth; nevertheless, this was only applicable to subclinical hypothyroidism with TSH >4.0 mU/L.
- 1 April 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (4) , 519-530
Effects of Levothyroxine Treatment on Fertility and Pregnancy Outcomes in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Subclinical hypothyroidism, elevated thyroid-stimulating hormone (TSH) and normal free thyroxine (FT4) levels, is associated with multiple adverse pregnancy outcomes. Despite the uncertainty regarding the effectiveness of levothyroxine treatment on pregnancy outcomes in subclinical hypothyroidism, levothyroxine is widely administered with a threshold TSH level of 2.5 mU/L. The aim of this study is to investigate the efficacy of periconceptional levothyroxine treatment for subclinical hypothyroidism, including TSH levels >2.5 mU/L, and identify the characteristics of subclinical hypothyroidism that can benefit from levothyroxine treatment. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials from inception to February 2023. We analyzed the pooled effects of levothyroxine on subclinical hypothyroidism before and during pregnancy. The main outcomes before pregnancy were live birth, pregnancy, and miscarriage. The main outcomes during pregnancy were live birth, miscarriage, and preterm birth. We conducted subgroup analyses to compare the effects of levothyroxine on subclinical hypothyroidism with TSH levels of 2.5–4.0 mU/L and >4.0 mU/L. Results: Of the 795 studies identified, 25 full-text articles were screened for eligibility. Finally, five studies on pre-conception treatment with 763 participants and seven studies on treatment during early pregnancy with 2,504 participants were analyzed. Pre-conception levothyroxine treatment showed no effect in improving live births and pregnancies, or decreasing miscarriages (risk ratio (RR):1.41; 95% confidence interval (CI):0.84–2.36, RR:1.73; 95%CI:0.88–3.39, and RR:0.46; 95%CI:0.11–2.00, respectively). Levothyroxine treatment during pregnancy showed no effect in improving live births (RR:1.03; 95%CI:0.98–1.09) or decreasing miscarriage rates (RR:0.99; 95%CI:0.65–1.51). The effect of levothyroxine treatment on preterm birth during pregnancy was significantly different depending on the TSH values (p=0.04); a positive effect was shown in the subclinical hypothyroidism subgroup with TSH >4.0 mU/L (RR:0.47; 95%CI:0.20–1.10), while no effect was shown in the subgroup with TSH 2.5-4.0 mU/L (RR:1.35; 95%CI:0.79–2.31). Conclusions: Pre-conceptional levothyroxine treatment does not improve fertility or decrease the incidence of miscarriages. However, further well-designed studies are needed for pre-conceptional treatment, especially in TSH >4.0 mU/L. Levothyroxine treatment during pregnancy had a positive effect on preterm birth; nevertheless, this was only applicable to subclinical hypothyroidism with TSH >4.0 mU/L.